The Biostatistics and Bioinformatics Core for the M. D. Anderson Specialized Programs of Research Excellence in myeloma will serve multiple needs with respect to the planning and conduct of the SPORE research. This resource will be used for hypothesis refinement, experimental design, data management, quality control, and informative presentation of results, and will be available for all projects ofthe SPORE. From a biostatistical perspective, design and analysis of laboratory and clinical projects will be performed in collaboration with Dr. Donald A. Berry, Dr. Veerabhadran Baladandayuthapani, and Dr. Heather Y. Lin. Data from the SPORE clinical trials and laboratory projects will be entered into a custom database. Among other advantages, this computerized database will facilitate continuous monitoring of clinical trial results and will allow for automated data audits. Thus, from inception to reporting, translational experiments will benefit from the Biostatistics and Bioinformatics Core that will be used to augment existing M. D. Anderson biostatistics resources and to align these considerable resources with SPORE research objectives.
The Specific Aims of the Biostatistics and Bioinformatics Core are:
Specific Aim 1 : To provide the statistical design, sample size and power calculations for each project.
Specific Aim 2 : To facilitate prospective collecfion, entry, quality control, and integration of data for the basic science experiments and clinical trials arising form the ongoing research ofthe SPORE.
Specific Aim 3 : To provide innovative statistical modeling, simulation techniques, and data analyses needed by the projects and other Cores to achieve their Specific Aims.
Specific Aim 4 : To ensure that the results of all projects are based on well-designed experiments and are appropriately interpreted.

Public Health Relevance

The Biostatisfics and Bioinformatics Core will be used for hypothesis refinement, experimental design, data management, quality control, and informafive presentation of results, and will be available for all projects of the SPORE.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Glitza, Isabella C; Lu, Gary; Shah, Rupin et al. (2015) Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma 56:602-7
Wen, Jianguo; Tao, Wenjing; Kuiatse, Isere et al. (2015) Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. Int J Cancer 136:991-1002
Hong, Bangxing; Li, Haiyan; Zhang, Mingjun et al. (2015) p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. Int J Cancer 136:34-43
Shi, Qiuling; Wang, Xin Shelley; Li, Guojun et al. (2015) Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer 121:1138-46
Wang, Xin Shelley; Shi, Qiuling; Williams, Loretta A et al. (2015) Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma 56:1335-41
Parmar, S; Kongtim, P; Champlin, R et al. (2014) Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant 49:1036-41
Chen, Zheng; Orlowski, Robert Z; Wang, Michael et al. (2014) Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 123:2204-8
San-Miguel, Jesús; Bladé, Joan; Shpilberg, Ofer et al. (2014) Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 123:4136-42
Srkalovic, Gordan; Hussein, Mohamad A; Hoering, Antje et al. (2014) A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med 3:1275-83
Ocio, Enrique M; Mitsiades, Constantine S; Orlowski, Robert Z et al. (2014) Future agents and treatment directions in multiple myeloma. Expert Rev Hematol 7:127-41

Showing the most recent 10 out of 79 publications